z-logo
open-access-imgOpen Access
RNA-seq analysis identified hormone-related genes associated with prognosis of triple negative breast cancer
Author(s) -
Fei Chen,
Yuancheng Li,
Na Qin,
Fengliang Wang,
Jiangbo Du,
Cheng Wang,
Fangzhi Du,
Tao Jiang,
Yue Jiang,
Juncheng Dai,
Zhibin Hu,
Cheng Lu,
Hongbing Shen
Publication year - 2020
Publication title -
journal of biomedical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.617
H-Index - 31
eISSN - 2352-4685
pISSN - 1674-8301
DOI - 10.7555/jbr.34.20190111
Subject(s) - triple negative breast cancer , breast cancer , oncology , medicine , gene , carcinogenesis , biology , cancer research , cancer , proportional hazards model , genetics
Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer that currently lacks effective biomarkers and therapeutic targets required to investigate the diagnosis and treatment of TNBC. Here we performed a comprehensive differential analysis of 165 TNBC samples by integrating RNA-seq data of breast tumor tissues and adjacent normal tissues from both our cohort and The Cancer Genome Atlas (TCGA). Pathway enrichment analysis was conducted to evaluate the biological function of TNBC-specific expressed genes. Further multivariate Cox proportional hazard regression was performed to evaluate the effect of these genes on TNBC prognosis. In this report, we identified a total of 148 TNBC-specific expressed genes that were primarily enriched in mammary gland morphogenesis and hormone levels related pathways, suggesting that mammary gland morphogenesis might play a unique role in TNBC patients differing from other breast cancer types. Further survival analysis revealed that nine genes ( FSIP1 , ADCY5 , FSD1 , HMSD , CMTM5 , AFF3 , CYP2A7 , ATP1A2 , and C11orf86 ) were significantly associated with the prognosis of TNBC patients, while three of them ( ADCY5 , CYP2A7 , and ATP1A2 ) were involved in the hormone-related pathways. These findings indicated the vital role of the hormone-related genes in TNBC tumorigenesis and may provide some independent prognostic markers as well as novel therapeutic targets for TNBC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom